6,7-二甲氧基-1-甲基-1,2,3,4-四氢异喹啉 | 63768-20-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 6,7-二甲氧基-1-甲基-1,2,3,4-四氢异喹啉
• 英文名称: 1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride
• 英文别名: 6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride；(rac)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride；6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline;hydrochloride
• CAS: 63768-20-7
• 化学式: C₁₇H₁₉NO₂*ClH
• 分子量: 305.804
• InChiKey: XCBCMNDFDVDUDF-UHFFFAOYSA-N

物化性质

• 熔点：
  251-254°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.36
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  35.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933499090
• 危险性防范说明：
  P233,P260,P261,P264,P271,P280,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  8-bromo-octanoic acid benzyloxy-amide 、 6,7-二甲氧基-1-甲基-1,2,3,4-四氢异喹啉 在 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 生成 8-(6,7-dimethoxy-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-octanoic acid benzyloxyamide
  参考文献：
  名称：

  Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors

  摘要：

  一种化合物的公式(I)，其中A、R1、R2和X具有规范中定义的含义，制造该化合物的方法以及含有具有HDAC抑制剂活性和抗细胞增殖活性的该化合物的药物组合物。

  公开号：

  US20040053960A1
• 作为产物：
  描述：

  2-phenyl-tetrahydro-(2H)-1,3-oxazine 、 3,4-二甲氧基苯乙胺 以 三氟乙酸 为溶剂， 反应 20.0h， 以88%的产率得到6,7-二甲氧基-1-甲基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  Singh; Singh, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1989, vol. 28, # 10, p. 802 - 805

  摘要：

  DOI：

文献信息

• P-Trifluoromethyl ligands derived from Josiphos in the Ir-catalysed hydrogenation of 3,4-dihydroisoquinoline hydrochlorides
  作者：R. Schwenk、A. Togni

  DOI：10.1039/c5dt02019k

  日期：——

  Ferrocenyl phosphines containing a stereogenic P-CF₃ group show improved selectivities in the Ir-catalysed hydrogenation of dihydroisoquinolinium derivatives.

  含有手性P-CF₃基团的二茂铁磷化物在铱催化的二氢异喹啉衍生物加氢反应中显示出改善的选择性。
• High affinity small molecule C5a receptor modulators
  申请人：Neurogen Corporation

  公开号：US06723743B1

  公开（公告）日：2004-04-20

  This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors, preferably human C5a receptors, Preferred compounds of the invention possess one or more, and preferably two or more, three or more, four or more, or all of the following properties in that they are; 1) multi-aryl in structure (having a plurality of un-fused or fused aryl groups), 2) heteroaryl in structure, 3) orally available in vivo (such that a sub-lethal or preferably a pharmaceutically acceptable oral dose can provide a detectable in vitro effect such as a reduction of C5a-induced neutropenia), 4) comprised of fewer than four, preferably fewer than three, or fewer than two, or no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar concentrations and preferably at sub-nanomolar concentrations. Specifically exemplified representative compounds include, but are not limited to optionally substituted arylimidazoles, optionally substituted arylpyridyls, optionally substituted aryl-substituted cycloalkylimidazoles, optionally substituted arylpyrazoles, optionally substituted benzimidazoles, optionally substituted aryl-substituted tetrahydroisoquinolines, and optionally substituted biaryl carboxamides. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

  该发明涉及低分子量、非肽、非肽类似物的有机分子，作为哺乳动物补体C5a受体的调节剂，最好是作为高亲和力C5a受体配体的分子，以及作为补体C5a受体的拮抗剂或逆向激动剂的这种配体，最好是人类C5a受体。该发明的优选化合物具有以下一个或多个性质，最好是两个或多个、三个或多个、四个或多个，或所有这些性质：1）结构上多芳基（具有多个未融合或融合的芳基基团）、2）结构上杂芳基、3）体内口服可用（使亚致死或最好是药学上可接受的口服剂量能够提供可检测的体外效应，如减少C5a诱导的中性粒细胞减少）、4）由少于四个、最好是少于三个、或少于两个、或无酰胺键组成，以及5）能够在纳摩尔浓度和最好是亚纳摩尔浓度下抑制白细胞趋化。具体例举的代表性化合物包括但不限于可选择取代的芳基咪唑、可选择取代的芳基吡啶、可选择取代的芳基取代环烷基咪唑、可选择取代的芳基吡唑、可选择取代的苯并咪唑、可选择取代的芳基取代四氢异喹啉和可选择取代的联苯基羧酰胺。该发明还涉及包含这些化合物的药物组合物。它还涉及将这些化合物用于治疗各种炎症和免疫系统疾病。此外，该发明还涉及将这些化合物用作C5a受体的定位探针。
• Substituted tetrahydroisoquinolines as C5a receptor modulators
  申请人：——

  公开号：US20040006069A1

  公开（公告）日：2004-01-08

  1 Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了替代四氢异喹啉和相关化合物。这些化合物是配体，可用于调节体内或体外的C5a受体活性，并且在治疗与人类、驯化伴侣动物和家畜动物中的病理性C5a受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的药物组成物和使用它们的方法，以及用于受体定位研究的配体使用方法。
• ANTI-ANGIOGENIC COMPOUND
  申请人：University College Dublin, National University of Ireland, Dublin

  公开号：EP3147280A1

  公开（公告）日：2017-03-29

  A compound of the formula: and salts thereof are useful as medicaments, especially for treatment of an angiogenesis-related disease or disorder.

  式中的化合物： 及其盐类可用作药物，特别是用于治疗与血管生成有关的疾病或紊乱。
• Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites
  作者：Sung-Woon Choi、David R. Elmaleh、Robert N. Hanson、Timothy M. Shoup、Alan J. Fischman

  DOI：10.1016/s0968-0896(02)00348-6

  日期：2002.12

  A series of (bisarylmethoxy)butylpiperidine derivatives was prepared and evaluated in vitro and in vivo to determine the structural requirements necessary for dual activity at the DAT and DA/5-HT receptor sites, These hybrid ligands, constructed by combining pharmacophores specific for the DAT and DA/5-HT receptors, could be useful drugs for treating cocaine addiction by assisting cocaine addicts in maintaining abstinence. The series was evaluated in vitro for DAT and DA/5-HT receptor activity and then selected compounds were tested in vivo for their effects on cocaine-induced hyperlocomotor activity (LMA). The majority of the new compounds demonstrated high to moderate affinity (4-191 nM) for the DAT with 4-hydroxy-4-phenylpiperidine analogues 14 and 15 possessing the greatest affinity. Compounds 15 and 22 exhibited the highest ratio of reuptake inhibition-to-binding (discrimination ratio, DR), 111 and 323, respectively. These derivatives had modest affinity and antagonistic activity for dopamine D-2/D-3 receptors. Compounds 9 and 15 (DR = 0.9 and 111. respectively) stimulated locomotor activity, whereas the other compounds suppressed this response, All compounds tested except for 17 and 21 attenuated cocaine-induced hyperlocomotion. (C) 2002 Elsevier Science Ltd. All rights reserved.